DailyIQ
Last updatedUpdating…

BAX·Baxter International Inc.

$24.36
+0.14 (+0.58%)
After Hours
High
$24.42
Open
$24.32
Market Cap
12.38B
52W High
$30.00
Low
$23.91
P. Close
$24.36
P/E
-
52W Low
$15.73
Fwd P/E
11.89
DailyIQ Est.
$28.35
Inst. Ownership
2.8%
Short Interest
4.56%
Days to Cover
4.5
Technical Score (1D)
55
BULLISH
News Sentiment
61
BULLISH
On Oct 6, Zacks analysts reported that Baxter International (BAX) was identified as a potential value play, assigning the stock a Buy rank with an A‑grade value rating. They noted that BAX trades at a price‑to‑earnings ratio below the industry average, suggesting the shares may be undervalued relative to peers. The analysts highlighted the company’s PEG ratio as falling within favorable ranges, supporting the view that the stock could be trading below intrinsic value. They also emphasized Baxter’s consistent earnings estimates and a positive outlook as key drivers for the recommendation. The commentary suggested that investors might consider BAX as a long‑term value opportunity amid broader market volatility.
LOW TARGET
$23 -5.6%
2 analysts
MEAN TARGET
$29 +17.9%
15 analysts
HIGH TARGET
$40 +64.2%
4 analysts
PRICE RANGE
$23.00 - $40.00
SB / B / H / S / SS
1/4/14/1/1
DAILYIQ EST.
$28.35 (+16.4%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Website
Symbol
BAX
Description
Baxter International Inc. is a global healthcare company specializing in a diverse range of medical products and therapies. Its core offerings include sterile intravenous solutions, infusion systems, and essential pharmaceuticals, serving critical needs in hospitals and various healthcare settings. Baxter's value proposition centers on providing life-sustaining and life-improving products, encompassing surgical tools, patient monitoring technologies, and respiratory care devices. The company's comprehensive product portfolio is distributed through a multi-channel approach, leveraging direct sales, distributors, and strategic partnerships. Operating internationally, Baxter's products are utilized across a broad spectrum of healthcare environments, making it a significant player in the global medical products market.
Bought (1Y)
0 shares
$0
Sold (1Y)
57,598 shares
$1.5M
Foster JuliePresident, Front Line Care
Tax Withholding2,098 shares2026-09-02
Hider Andrew P.President and CEO
Tax Withholding54,276 shares2026-09-02
Teaff JamesPresident, CCS
Tax Withholding750 shares2026-09-01
Teaff JamesPresident, CCS
Tax Withholding321 shares2026-06-02
Wallace Steven P.President, Adv. Surgery
Tax Withholding153 shares2026-06-02
56/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
30.1%
Net Margin
-8.5%
Revenue CAGR
0.0%
Current Ratio
2.31x
Debt / Equity
1.54x
Return on Equity
-15.6%
Earnings Summary
Baxter International Inc. is a global healthcare company that specializes in sterile intravenous solutions, infusion systems, and essential pharmaceuticals, serving hospitals and other medical settings worldwide. Operating in the medical instruments and supplies sector, Baxter’s diversified portfolio includes surgical tools, patient monitoring technologies, and respiratory care devices, positioning it as a key player in the broader medical products market. In the most recent two quarters, Baxter posted EPS of $0.55 in Q1 2025 and $0.54 in Q2 2025, both below analyst estimates of $0.4832 and $0.60999 respectively, while revenue rose to $2.815 billion in Q2 from $2.625 billion in Q1, reflecting a 7.2% increase. The company’s Q3 2025 EPS of $0.69 beat the $0.5979 estimate, and revenue climbed to $2.835 billion, marking a 1.4% rise from Q2. Historically, Baxter has shown a steady YoY revenue growth trajectory, with Q4 2025 revenue at $2.974 billion up 7.4% from the prior year, and EPS consistently beating estimates in the last three quarters, though Q2 2025 EPS fell short. This pattern indicates robust top‑line momentum even when earnings miss guidance, suggesting that margin pressures may be moderating profitability. Recent news highlights a 2026 sales outlook upgrade to 3‑4% growth and adjusted earnings guidance of $1.95‑$2.15 per share, driven by stronger organic sales and tariff‑refund benefits; the company also announced a CFO transition to John Rogers and an upsized cash tender offer, underscoring a focus on financial discipline and debt reduction.

EPS

EstBeatMiss
$0.25$0.38$0.50$0.62$0.75Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.52 - -
Q2'26$0.37$0.56+52.2%
Q1'26$0.31$0.36+15.7%
Q4'25$0.33$0.44+34.0%
Q3'25$0.60$0.69+15.4%
Q2'25$0.61$0.54-11.5%

Revenue

EstBeatMiss
$2.5B$2.7B$2.8B$2.9B$3.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.9B - -
Q2'26$2.8B$3.0B+4.9%
Q1'26$2.6B$2.7B+2.1%
Q4'25$2.6B$3.0B+14.2%
Q3'25 - $2.8B -
Q2'25 - $2.8B -

Market Data

BAX Stock Snapshot

NEUTRAL55/100
$24.29−$0.07 (0.3%)
Market cap
12.38B
Day range
$23.91 – $24.42
News sentiment
61/100 · Bullish
Analyst target
$28.73 (+18.3%)
Consensus
Hold · 21 analysts
52-week range+54.4% off low · -19.0% from high
$15.73$30.00
Price $24.29 DailyIQ Est. $28.35

BAX is in a holding pattern - neither trend nor momentum has taken control. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into BAX?

RICH

At today's price, Baxter International Inc. needs to grow free cash flow about 3.1% a year for the next 10 years to justify its valuation at a 6.80% cost of capital. Over its actual history it has compounded free cash flow at -6.4% a year, so the market is asking for 9.5 percentage points above its own delivered rate. On that basis BAX looks priced above what its own growth record supports.

Implied FCF growth
3.1%
Historical FCF CAGR
-6.4%
Growth gap
+9.5 pts
Verdict
RICH
Discount rate (WACC)
6.80%
Beta
0.93

Behaviour On Record

What BAX's own history says about today's numbers

Realized volatility (21d)
28.2% 72nd pct
Below its peak
-74.4%
vs 200-day average
+16.2%
Up days (1y)
47%

Baxter International Inc. is currently running 28.2% annualised volatility over the last 21 sessions. Measured against BAX's own 13 years of daily returns rather than a market-wide average, that is the 72nd percentile — a little above its own norm, against a typical reading of 22.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BAX is trading -74.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.0%, and the deepest was -52.1% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +16.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 95th percentile — a wider gap than this stock usually carries. Over the past year BAX closed higher on 47% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, BAX finished the month higher 4 of 13 times, with a median return of -2.7% and an average of -4.7%. Its strongest month historically has been April at +2.3% on average, its weakest October at -4.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BAX has opened more than 2% away from the prior close in 93 of 3,267 sessions (2.8% of the time), with the largest gaps running +5.4% and -5.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BAX moved an average of 2.0% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.4% and a largest of +4.5%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against BAX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BAX's sector?

Baxter International Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for BAX?

CallsPuts

For Baxter International Inc.'s nearest expiry (2026-10-09, 3 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.39), with at-the-money implied volatility around 53.9%. The options market is pricing roughly a ±4.5% move by that expiry — a range of about $22.43–$24.55.

Put/call ratio (2026-10-09)
0.39
ATM implied volatility
53.9%
Total open interest
747
Expected move by 2026-10-09
±4.5% ($22.43–$24.55)

Analyst Rating Changes

Are analysts turning bullish or bearish on BAX?

TD Cowen most recently reiterated its rating on Baxter International Inc. to Hold on Jul 31, 2026 with a price target of $29 (from $24). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
TD Cowen — Hold
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Jul 31, 2026TD CowenMaintainedHold$24 → $29
Jul 31, 2026Wells FargoMaintainedEqual-Weight$19 → $23
Jul 31, 2026StifelMaintainedHold$24 → $28
Jul 31, 2026CitigroupUpgradeSell → Neutral$17 → $28
Jul 28, 2026UBSMaintainedNeutral$19 → $25
Jul 28, 2026StifelMaintainedHold$19 → $24
Jul 27, 2026TD CowenMaintainedHold$20 → $24
Jul 15, 2026Goldman SachsMaintainedNeutral$19 → $21
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$22 → $24
May 28, 2026CitigroupDowngradeNeutral → Sell$19 → $17
May 4, 2026BarclaysMaintainedOverweight$25 → $27
Apr 6, 2026Evercore ISI GroupMaintainedOutperform$23 → $22

BAX Competitive Positioning

Baxter International Inc. (BAX) is tracked alongside these names in Medical Instruments & Supplies on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

61/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Zacks analysts identified Baxter International (BAX) as a compelling value investment, citing its strong Zacks Rank #2 (Buy) and high Value grade. The firm highlighted BAX’s favorable earnings estimates and recent positive revisions, suggesting potential upside for investors. Analysts noted that BAX’s current share price appears undervalued relative to its fundamentals, positioning it as a top pick for value-oriented portfolios. The recommendation is based on quantitative metrics rather than speculative hype, underscoring a data‑driven endorsement.
What did this article say?
Baxter International (BAX) saw its full‑year earnings estimate rise 6.5% in the last quarter, reflecting a shift in analyst sentiment toward a more positive outlook. The company holds a Zacks Rank of #2 (Buy), placing it among the top performers in the medical sector. This upgrade suggests that BAX is expected to outperform peers over the next one to three months, though the move is not considered transformative.
What did this article say?
Citigroup reduced its price target for Baxter International from $28 to $27 while keeping a neutral rating. The adjustment reflects a modest reassessment of the company’s near‑term earnings outlook. The change does not alter the overall hold consensus among analysts. Investors may view the move as a slight headwind but not a material shift in expectations.
What did this article say?
Baxter International released its 2026 Connected Hospital Report, surveying 150 IT and nursing leaders to assess technology maturity across U.S. hospitals. The report outlines a four-stage framework—early, developing, advancing, and leading—to benchmark progress and prioritize initiatives. It emphasizes the company’s commitment to supporting data‑driven care environments, though it does not indicate immediate financial or operational impact for BAX.
What did this article say?
Baxter International announced a portfolio reset aimed at operational efficiency and growth in connected care and advanced surgery. The company highlighted solid demand in select businesses and improving execution as drivers of its outlook. However, margin pressure from manufacturing costs, tariffs, pricing constraints, Novum IQ regulatory issues, and procurement challenges in China were identified as near‑term headwinds. Despite these risks, analysts maintained a hold rating, noting a 23% year‑to‑date share gain versus a 21.3% industry decline.
What did this article say?
Baxter International (BAX) was highlighted as a stock to sell due to declining revenue growth and shrinking earnings per share over the past two years. The company’s historically strong presence in dialysis, IV solutions, and surgical products has been undermined by softer demand in key markets. Analysts noted that each sale has become less profitable, with EPS falling 8.5% annually, a trend worse than its revenue decline. The recommendation reflects a negative outlook for BAX’s short‑term financial performance.
What did this article say?
Baxter International’s CEO Andrew Hider and Investor Relations head Kevin Moran participated in a Wells Fargo 21st Annual Healthcare Conference call. The discussion focused on the company’s ongoing product portfolio and market positioning without announcing new guidance or material developments. No changes to earnings forecasts or strategic initiatives were disclosed, leaving the market view unchanged.

Technical Analysis

Real-time indicators across multiple timeframes

55
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
3 tracked managers · $308.51M combined position · 1 adding, 1 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Geode Capital Management, LLC▲ Buy14,123,6892.77%$300.59M2026-08-12
Neuberger Berman Group LLC▼ Sell245,4010.05%$5.23M2026-08-13
UBS O'Connor (UBS Asset Management)• Hold88,7870.02%$2.69M2025-08-14
Q2 2026 flow:360.7K sh bought ($7.68M)92.2K sh sold ($1.97M)net +268.5K sh (+$5.71M)
Congressional Trading Activity
8 disclosed trades · ~$64.0K est. traded value · 4 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-09-252025-10-22
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Dan SullivanSenateAK▼ Sell$1K - $15K2022-11-302023-07-26